Attenuation of colon carcinoma tumor spread by intravenous immunoglobulin.
The impact of IVIg on metastatic capacity of CT26 murine colon carcinoma cells was studied using in vitro and in vivo methods. IVIg inhibited CT26 cell proliferation and invasion through an extracellular matrix in a dose- and time-dependent manner. Systemic treatment of mice with IVIg significantly inhibited metastatic potential of CT26 colon carcinoma cells observed as tumor nodules and lung weight reduction. Treating CT26 cell-implanted rabbit corneas with IVIg led to shrinking and complete disappearance of tumor mass in 10 days. These results provide the evidence that IVIg may be considered as a supportive therapy for inhibition of colon carcinoma tumor spread.
Damianovich
Maya
M
Center for Autoimmune Diseases and Department of Medicine B, The Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Hashomer, Israel.
Solomon
Arieh Sorin
AS
Blank
Miri
M
Shoenfeld
Yehuda
Y
D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003110:Colonic Neoplasms / Q000276:immunology* / Q000628:therapy*; D005134:Eye Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy; D016756:Immunoglobulins, Intravenous / Q000276:immunology* / Q000627:therapeutic use*; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000556:secondary / Q000628:therapy; D008297:Male; D051379:Mice; D009361:Neoplasm Invasiveness; D011817:Rabbits; D023041:Xenograft Model Antitumor Assays
D016756:Immunoglobulins, Intravenous